Upon tumor-specific release, allicin-mediated redox activation converts As<sup>5+</sup> to cytotoxic As<sup>3+</sup>, enabling selective p53 reactivation, concurrent ATR inhibition, and H<sub>2</sub>S-amplified apoptosis. The gene discussed is TP53; the disease is neoplasm.